Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Eye Care Firms Ride New Products, Overseas Growth To Fuel Stocks In 2004

This article was originally published in The Gray Sheet

Executive Summary

Contact lens manufacturers The Cooper Companies and Bausch & Lomb are taking aim at the Asian specialty lens market to sustain growth experienced in 2003, following a rebound in stock prices for ophthalmic device manufacturers after a two-year lull

You may also be interested in...



Visx Eyes Expanded CustomVue Indications, Readies U.S. Presbyopia Trial

Visx is counting on expanded hyperopia and myopia claims to its CustomVue wavefront ablation system to spur 8%-10% sales growth in 2005

Visx Eyes Expanded CustomVue Indications, Readies U.S. Presbyopia Trial

Visx is counting on expanded hyperopia and myopia claims to its CustomVue wavefront ablation system to spur 8%-10% sales growth in 2005

Ocular Sciences Acquisition Puts Ciba, J&J/Vistakon In Cooper’s Sights

Cooper Companies' planned Ocular Sciences purchase positions the firm to achieve $1 bil. in annual contact lens sales by 2007, according to CEO Thomas Bender

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT019559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel